查詢結果分析
相關文獻
- Effects of Intraarticular Botulinum Toxin A in the Treatment of Ankle Osteoarthritis
- 燻煙及亞硝酸鈉對常溫貯藏去皮雞腿製品化學特性及肉毒桿菌毒素之影響
- Botulinum Toxin Type A: From Toxin to Therapeutic Agent
- Treatment of Cerebral Palsy with Botulinum Toxin: Evaluation with Gross Motor Function Measure
- A型肉毒桿菌毒素治療半面痙攣:病例報告
- 一帖不可思議的良藥--肉毒桿菌毒素
- An Outbreak of Type-C Botulism in Broilers
- 肉毒桿菌毒素A在眼科學的應用
- 肉毒桿菌毒素處理痙攣型腦性麻痺的成效
- 肉毒桿菌毒素
頁籤選單縮合
題 名 | Effects of Intraarticular Botulinum Toxin A in the Treatment of Ankle Osteoarthritis=肉毒桿菌毒素用在踝退化性關節炎之療效研究 |
---|---|
作 者 | 孫淑芬; 許健威; 周怡君; 王友農; 黃巧雯; 周美嘉; 王志龍; | 書刊名 | 臺灣復健醫學雜誌 |
卷 期 | 40:3 2012.09[民101.09] |
頁 次 | 頁127-134 |
分類號 | 415.952 |
關鍵詞 | 踝退化性關節炎; 肉毒桿菌毒素; 關節內注射; Ankle osteoarthritis; Botulinum toxin; Intraarticular injection; |
語 文 | 英文(English) |
中文摘要 | 背景:目前已有初步的證據顯示關節內注射肉毒桿菌毒素能有效改善疼痛。本研究目的將探討關節內注射肉毒桿菌毒素用在踝關節退化性關節炎,在疼痛及功能改善方面的療效。方法:本研究採前瞻性方法,在醫學中心進行,收錄臨床症狀及X光顯示為踝退化性關節炎且至少六個月之病人,進入研究後所有病人接受踝關節內注射肉毒桿菌毒素(100單位於2cc生理食鹽水)。所有注射由同一經驗豐富的醫師施行。主要評估項目為踝退化性關節炎指數(AOS),次要評估項目包括美國足踝醫學會踝-後腳分數(AOFAS)、疼痛度(VAS)、踝關節活動角度(ROM)、單腳站立測試(SLS)、計時的“起立向前走”測試(TUG)及止痛藥使用量,以上測量將在注射前、注射後二星期、第一、三及六個月時做各項評估。病患滿意度則在注射後二星期、第一、三及六個月時做評估;局部或全身性不良反應,也將予以記錄。結果:15位病患加入此研究,有13位病患完成研究。所有病患在評估項目AOS、AOFAS、VAS、SLS、TUG皆有明顯的改善,且效果持續至少六個月。止痛藥使用量在研究期間也有明顯的下降。踝關節活動角度則無明顯的改變。病患的整體滿意度高,而且沒有任何嚴重的不良反應。結論:關節注射肉毒桿菌毒素用在踝退化性關節炎耐受性佳,且能有效減輕疼痛、失能及改善平衡功能。療效至少持續六個月。未來的研究需要更嚴謹控制及更多的參與者加入來證實療效。 |
英文摘要 | Background: Preliminary evidence suggests that Botulinum toxin type A (BoNT-A) injected intraarticularly into painful joints has a significant nociceptive effect. The purpose of this study is to investigate the effects of intraarticular BoNT-A on the pain and physical function for patients with ankle osteoarthritis (OA).Method: A prospective study with 6 months follow-up done in a university-affiliated tertiary care medical center, patients with symptoms and radiographic evidence of ankle OA for at least 6 months were recruited. Patients received intraarticular injections of 100 units of BoNT-A in 2 cc of normal saline. The injections were performed by the same experienced doctor. The primary outcome were assessed with the ankle function using the Ankle Osteoarthritis Scale (AOS) score. Secondary outcomes were assessed with American Orthopaedic Foot and Ankle Society (AOFAS) ankle/hindfoot score, VAS, ankle sagittal range of motion (ROM), single leg stance test (SLS), Timed "Up-and-Go" test (TUG) and consumption of rescue analgesics. These tests were conducted pre-injection and at 2 weeks, 1 month, 3 months, and 6 months post injection. Patients' global satisfaction was assessed at 2 weeks, 1 month, 3 months, and 6 months post injection. Adverse events during the study period were recorded also.Results: Fifteen patients were recruited and 13 patients completed the study. All patients showed significant improvements in their AOS, AOFAS, VAS, SLS and TUG scores. These improvement persisted for at least 6 months. Acetaminophen consumption dropped significantly following treatment (p<0.001). Ankle sagittal ROM did not change significantly throughout the study period. Patients' global satisfaction rate was high and no serious adverse events were reported.Conclusions: Intraarticular BoNT-A injection to the ankle joint is well tolerated. It effectively reduces pain, disability as well as improves balance function in patients with ankle OA. These effects can last for 6 months. Future studies that include rigorously controlled designs and larger number of patients would be necessary to determine the efficacy for the treatment of ankle OA. |
本系統中英文摘要資訊取自各篇刊載內容。